Does tablet Nebivolol improve disability in Stroke patients?
- Conditions
- Health Condition 1: null- age 18 to 75 yrs of both gender.Onset of stroke symptoms (ischemic) within 6 to 36 hours prior to beginning of treatment.NIHSS score more than 5. SBP more than 140 mmHg or DBP more than 90 mmHg
- Registration Number
- CTRI/2017/08/009364
- Lead Sponsor
- HINDU MISSION HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Onset of stroke symptoms ischemic within 6 to 36 hours prior to beginning of treatment.
NIHSS score greater or equal to 5.
Known case of hypertension or SBP more than 140 mmHg or DBP more than 90 mmHg.
Haemorrhagic Stroke, other Central Nervous System (CNS) diseases, including brain tumor, demyelinating diseases, inflammatory diseases, a history of craniotomy or severe brain injuries and idiopathic intracranial hypertension.
Any known contra-indication to Nebivolol such as severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome, (unless a permanent pacemaker is in place), severe hepatic impairment (Child-Pugh >B).
Acute or chronic renal failure.
Pre-existing infectious disease requiring other antibiotic therapy.
Pregnant Women.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is to compare National Institute of Health Stroke Scale (NIHSS) score modified Barthel Index (mBI) and modified Rankin Scale (mRS) score at admission and on days 30 and 90 <br/ ><br>Timepoint: baseline 10 days 30 days and 90 days
- Secondary Outcome Measures
Name Time Method Adverse Events MonitoringTimepoint: baseline 10 days 30 days and 90 days